Accelerate to discover

Homepage>Discover>Assessment of CAR T Cell killing capacity against solid tumors-Thursday, October 20, 2016, 5 pm CEST

Jan 17, 2019

Cytek Biosciences and De Novo Software are proud to announce a collaboration that allows you to work with your spectral...

IncuCyte webinar recording: CAR T-cell therapy, frontiers in cancer Immunotherapy

Jan 11, 2019

The success of immune checkpoint blockade adds new therapeutic category to Cancers are the most heterogenous group of...

Bioflux webinar: Blockade of CD62L inhibits CLL cell interaction with vascular endothelium

Nov 22, 2018

CD62L (L-selectin) is a key adhesion molecule that promotes cell tethering and rolling along the vascular endothelium...

Xcell Bio webinar: AVATAR system, to control cell state to get better cells, fast

Oct 30, 2018

Dr. Schneider will show examples of data from customers who have incorporated pressure along with oxygen to recreate...

Feb 20, 2019

Webinar Tuning Microenvironment to Control Cells for Improved Disease Modeling & Immunotherapy Work

Jul 16, 2018

The company producing Avatar, xCELL biosciences have organized a webinar about the tuning of microenvironment to...

How microCT can provide insight into dynamic disease processes webinar

Jun 19, 2018

Professor Vande Velde will describe how high-field MRI and low dose microCT complement each other; where microCT gives...

Photoacoustic Imaging of placental oxygenation

May 16, 2018

Watch the new webinar about photoacoustick imaging presented by Dr. Liliya M. Yamaleyeva, Assistant Professor in the...

Feb 20, 2019

BioFlux webinar: Introducing new plates and capabilities of BioFlux microfluidic system

May 13, 2018

BioFlux biofilm assays can now be performed on the popular catheter material polydimethylsiloxane (PDMS). Silicone...

Show all topics (10)

Assessment of CAR T Cell killing capacity against solid tumors-Thursday, October 20, 2016, 5 pm CEST

Oct 13, 2016

Nabil Ahmed, M.D., M.P.H. Associate Professor of Pediatrics, Baylor College of Medicine (USA).

Robust CAR design and sensitive yet realistic functional testing will be required in order to improve the efficacy of CAR T cell therapies targeting solid tumors. We have used the xCELLigence Real-Time Cell Analyzer as a high-throughput platform to test multiple CAR components including extracellular domains (including bi-specifics), signaling endo-domains, as well as next-generation CAR T cell products that are inherently resistant to checkpoint blockade. This platform has proven very sensitive to subtle yet longitudinally meaningful differences in CAR design, and has made it possible to evaluate T cell products in a "stress test" that is more representative of early phase trial requirements.

Register now

Webinar

Related technologies: Real-time, label free cell analysis

Get more info